NICE Issues Final Draft Guidance Recommending Tezspire for Severe Asthma

The UK’s National Institute for Health and Care Excellence (NICE) released a final draft guidance recommending the use of Amgen and Astrazeneca’s Tezspire in maintenance treatment for some patients with severe asthma. The biologic is the only one of its kind, targeting an important asthma-related inflammatory protein.

According to Emily Kimber, “The final draft guidance from the National Institute for Health and Care Excellence (NICE) specifically applies to patients who are inadequately controlled with high dose inhaled corticosteroids plus another maintenance therapy. Eligible patients will have had three or more exacerbations in the previous year, or are having maintenance oral corticosteroids.”

To read more, click here.

(Source: PM Live, March 30^th, 2023)